A citation-based method for searching scientific literature

F Dehdashti, J E Mortimer, B A Siegel, L K Griffeth, T J Bonasera, M J Fusselman, D D Detert, P D Cutler, J A Katzenellenbogen, M J Welch. J Nucl Med 1995
Times Cited: 252







List of co-cited articles
925 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
Lanell M Peterson, David A Mankoff, Thomas Lawton, Kevin Yagle, Erin K Schubert, Svetlana Stekhova, Allen Gown, Jeanne M Link, Timothy Tewson, Kenneth A Krohn. J Nucl Med 2008
164
58

Breast cancer: PET imaging of estrogen receptors.
M A Mintun, M J Welch, B A Siegel, C J Mathias, J W Brodack, A H McGuire, J A Katzenellenbogen. Radiology 1988
327
50

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Hannah M Linden, Svetlana A Stekhova, Jeanne M Link, Julie R Gralow, Robert B Livingston, Georgiana K Ellis, Philip H Petra, Lanell M Peterson, Erin K Schubert, Lisa K Dunnwald,[...]. J Clin Oncol 2006
257
48


Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
J E Mortimer, F Dehdashti, B A Siegel, K Trinkaus, J A Katzenellenbogen, M J Welch. J Clin Oncol 2001
277
40

Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.
A H McGuire, F Dehdashti, B A Siegel, A P Lyss, J W Brodack, C J Mathias, M A Mintun, J A Katzenellenbogen, M J Welch. J Nucl Med 1991
218
37

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
F Dehdashti, F L Flanagan, J E Mortimer, J A Katzenellenbogen, M J Welch, B A Siegel. Eur J Nucl Med 1999
209
32

PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Farrokh Dehdashti, Joanne E Mortimer, Kathryn Trinkaus, Michael J Naughton, Matthew Ellis, John A Katzenellenbogen, Michael J Welch, Barry A Siegel. Breast Cancer Res Treat 2009
145
31

Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats.
D O Kiesewetter, M R Kilbourn, S W Landvatter, D F Heiman, J A Katzenellenbogen, M J Welch. J Nucl Med 1984
203
29

Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Hannah M Linden, Brenda F Kurland, Lanell M Peterson, Erin K Schubert, Julie R Gralow, Jennifer M Specht, Georgiana K Ellis, Thomas J Lawton, Robert B Livingston, Philip H Petra,[...]. Clin Cancer Res 2011
84
34

PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
Michel van Kruchten, Andor W J M Glaudemans, Erik F J de Vries, Regina G H Beets-Tan, Carolien P Schröder, Rudi A Dierckx, Elisabeth G E de Vries, Geke A P Hospers. J Nucl Med 2012
102
24

PET imaging of oestrogen receptors in patients with breast cancer.
Michel van Kruchten, Elisabeth G E de Vries, Myles Brown, Erik F J de Vries, Andor W J M Glaudemans, Rudi A J O Dierckx, Carolien P Schröder, Geke A P Hospers. Lancet Oncol 2013
134
24

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
Andreas Buck, Holger Schirrmeister, Thorsten Kühn, Changxian Shen, Thomas Kalker, Jörg Kotzerke, Anja Dankerl, Gerhard Glatting, Sven Reske, Torsten Mattfeldt. Eur J Nucl Med Mol Imaging 2002
215
23

Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
Lanell M Peterson, Brenda F Kurland, Jeanne M Link, Erin K Schubert, Svetlana Stekhova, Hannah M Linden, David A Mankoff. Nucl Med Biol 2011
43
51

Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Mary L Gemignani, Sujata Patil, Venkatraman E Seshan, Michelle Sampson, John L Humm, Jason S Lewis, Edi Brogi, Steven M Larson, Monica Morrow, Neeta Pandit-Taskar. J Nucl Med 2013
42
52

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
N Avril, M Menzel, J Dose, M Schelling, W Weber, F Jänicke, W Nathrath, M Schwaiger. J Nucl Med 2001
305
21

Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
Brenda F Kurland, Lanell M Peterson, Jean H Lee, Hannah M Linden, Erin K Schubert, Lisa K Dunnwald, Jeanne M Link, Kenneth A Krohn, David A Mankoff. J Nucl Med 2011
47
40

[18F]fluoroestradiol radiation dosimetry in human PET studies.
D A Mankoff, L M Peterson, T J Tewson, J M Link, J R Gralow, M M Graham, K A Krohn. J Nucl Med 2001
58
29

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.
Reinhard Bos, Jacobus J M van Der Hoeven, Elsken van Der Wall, Petra van Der Groep, Paul J van Diest, Emile F I Comans, Urvi Joshi, Gregg L Semenza, Otto S Hoekstra, Adriaan A Lammertsma,[...]. J Clin Oncol 2002
415
16





Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.
David Groheux, Sylvie Giacchetti, Jean-Luc Moretti, Raphael Porcher, Marc Espié, Jacqueline Lehmann-Che, Anne de Roquancourt, Anne-Sophie Hamy, Caroline Cuvier, Laetitia Vercellino,[...]. Eur J Nucl Med Mol Imaging 2011
251
15

A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
Lanell M Peterson, Brenda F Kurland, Erin K Schubert, Jeanne M Link, V K Gadi, Jennifer M Specht, Janet F Eary, Peggy Porter, Lalitha K Shankar, David A Mankoff,[...]. Mol Imaging Biol 2014
53
28

Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
Michel van Kruchten, Elisabeth G de Vries, Andor W Glaudemans, Meta C van Lanschot, Martijn van Faassen, Ido P Kema, Myles Brown, Carolien P Schröder, Erik F de Vries, Geke A Hospers. Cancer Discov 2015
100
15

Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Laura Kenny, R Charles Coombes, David M Vigushin, Adil Al-Nahhas, Sami Shousha, Eric O Aboagye. Eur J Nucl Med Mol Imaging 2007
209
14

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
14

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
Alina Berriolo-Riedinger, Claude Touzery, Jean-Marc Riedinger, Michel Toubeau, Bruno Coudert, Laurent Arnould, Christophe Boichot, Alexandre Cochet, Pierre Fumoleau, François Brunotte. Eur J Nucl Med Mol Imaging 2007
130
13

Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP).
T J Tewson, D A Mankoff, L M Peterson, I Woo, P Petra. Nucl Med Biol 1999
37
35

Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
David Fuster, Joan Duch, Pilar Paredes, Martín Velasco, Montserrat Muñoz, Gorane Santamaría, Montserrat Fontanillas, Francesca Pons. J Clin Oncol 2008
189
12

Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation.
F Crippa, E Seregni, R Agresti, C Chiesa, C Pascali, A Bogni, D Decise, V De Sanctis, M Greco, M G Daidone,[...]. Eur J Nucl Med 1998
136
12

Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione.
Farrokh Dehdashti, Richard Laforest, Feng Gao, Rebecca L Aft, Carmen S Dence, Dong Zhou, Kooresh I Shoghi, Barry A Siegel, John A Katzenellenbogen, Michael J Welch. J Nucl Med 2012
54
22

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.
Eitan Amir, Naomi Miller, William Geddie, Orit Freedman, Farrah Kassam, Christine Simmons, Maria Oldfield, George Dranitsaris, George Tomlinson, Andreas Laupacis,[...]. J Clin Oncol 2012
304
12

18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
Geraldine J Liao, Amy S Clark, Erin K Schubert, David A Mankoff. J Nucl Med 2016
50
24

Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer.
Rakesh Kumar, Anil Chauhan, Hongming Zhuang, Prem Chandra, Mitchell Schnall, Abass Alavi. Breast Cancer Res Treat 2006
131
11

Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer.
A Gil-Rendo, F Martínez-Regueira, G Zornoza, M J García-Velloso, C Beorlegui, N Rodriguez-Spiteri. Br J Surg 2009
118
11

Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tetsuya Tsujikawa, Yoshio Yoshida, Takashi Kudo, Yasushi Kiyono, Tetsuji Kurokawa, Masato Kobayashi, Tatsuro Tsuchida, Yasuhisa Fujibayashi, Fumikazu Kotsuji, Hidehiko Okazawa. J Nucl Med 2009
49
22

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
11

Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
Amy M Fowler, Szeman Ruby Chan, Terry L Sharp, Nicole M Fettig, Dong Zhou, Carmen S Dence, Kathryn E Carlson, M Jeyakumar, John A Katzenellenbogen, Robert D Schreiber,[...]. J Nucl Med 2012
51
21

Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
E C Dijkers, T H Oude Munnink, J G Kosterink, A H Brouwers, P L Jager, J R de Jong, G A van Dongen, C P Schröder, M N Lub-de Hooge, E G de Vries. Clin Pharmacol Ther 2010
518
11

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Shigeto Ueda, Hitoshi Tsuda, Hideki Asakawa, Takashi Shigekawa, Kazuhiko Fukatsu, Nobuo Kondo, Mikio Yamamoto, Yukihiro Hama, Katsumi Tamura, Jiro Ishida,[...]. Jpn J Clin Oncol 2008
155
10

PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
Brigitte Smyczek-Gargya, Nikos Fersis, Helmut Dittmann, Ulrich Vogel, Gerald Reischl, Hans-Juergen Machulla, Diethelm Wallwiener, Roland Bares, Bernhard M Dohmen. Eur J Nucl Med Mol Imaging 2004
129
10

Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.
Betty S Pio, Cecilia K Park, Richard Pietras, Wei-Ann Hsueh, Nagichettiar Satyamurthy, Mark D Pegram, Johannes Czernin, Michael E Phelps, Daniel H S Silverman. Mol Imaging Biol 2006
175
10

FDG PET, PET/CT, and breast cancer imaging.
Eric L Rosen, William B Eubank, David A Mankoff. Radiographics 2007
141
10

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
10

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
10

The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.
Ayse Mavi, Tevfik F Cermik, Muammer Urhan, Halis Puskulcu, Sandip Basu, Jian Q Yu, Hongming Zhuang, Brian Czerniecki, Abass Alavi. J Nucl Med 2007
63
15

The relationship between FDG uptake in PET scans and biological behavior in breast cancer.
Wataru Shimoda, Mitsuhiro Hayashi, Koji Murakami, Tetsunari Oyama, Masakatsu Sunagawa. Breast Cancer 2007
71
14

Tumor receptor imaging.
David A Mankoff, Jeanne M Link, Hannah M Linden, Lavanya Sundararajan, Kenneth A Krohn. J Nucl Med 2008
106
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.